Adalimumab trough levels predict Crohn's disease clinical course

Dig Liver Dis. 2018 Feb;50(2):204-206. doi: 10.1016/j.dld.2017.09.139. Epub 2017 Oct 28.

Authors

Davide Giuseppe Ribaldone¹, Tilde Manetta², Giulio Mengozzi², Giorgio Maria Saracco³, Rinaldo Pellicano⁴, Marco Astegiano⁴

Affiliations

¹ Department of Medical Sciences, Division of Gastroenterology, University of Turin, Turin, Italy. Electronic address: dribaldo@unito.it.
² Biochemical Laboratory, A.O.U. City of Health and Science, Turin, Italy.
³ Department of Medical Sciences, Division of Gastroenterology, University of Turin, Turin, Italy.
⁴ Department of General and Specialistic Medicine, Gastroenterology-U, City of Health and Science of Turin, Turin, Italy.

PMID: 29129478
DOI: 10.1016/j.dld.2017.09.139

No abstract available

Publication types

Letter
Observational Study

MeSH terms

Adalimumab / blood
Adalimumab / therapeutic use*
Adolescent
Adult
Aged
Anti-Inflammatory Agents / therapeutic use*
Azathioprine / blood
Azathioprine / therapeutic use*
Crohn Disease / drug therapy*
Drug Therapy, Combination
Female
Humans
Italy
Male
Middle Aged
Prospective Studies
ROC Curve
Treatment Outcome
Young Adult

Substances

Anti-Inflammatory Agents
Adalimumab
Azathioprine